Zai Lab (ZLAB) - Stock Price & Dividends

Zai Lab Ltd (NASDAQ: ZLAB) focuses on developing and bringing to market various therapies for a range of medical conditions like oncology, autoimmune disorders, infectious diseases, and neuroscience in both Mainland China and Hong Kong.

Some of the products in their portfolio include Zejula, a small-molecule poly polymerase 1/2 inhibitor; Optune, a device that aids in delivering tumor treating fields; NUZYRA for bacterial infections like acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, used in treating gastrointestinal stromal tumors.

They are also actively working on developing new treatments like Odronextamab, targeting various lymphomas; Repotrectinib, a tyrosine kinase inhibitor focused on specific cancer types; and Margetuximab designed for breast and gastroesophageal cancers.

In addition to the aforementioned, their innovative pipeline also includes potential treatments like Tisotumab vedotin, Adagrasib for various cancers, and Bemarituzumab for gastric and gastroesophageal junction cancer.

Established in 2013 and headquartered in Shanghai, China, Zai Lab Ltd is committed to advancing medical solutions in diverse therapeutic areas. For more information, you can visit their website at https://www.zailaboratory.com.